Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens

US5871900A · kind A · utility

Assignee

• Cerus Corporation · US

Inventors

• Susan Wollowitz · Walnut Creek, US
• Stephen T. Isaacs · Orinda, US
• Henry Rapoport · Berkeley, US
• Hans Peter Spielmann · Lexington, US
• Aileen Nerio · Fremont, US

Key dates

• Filing date: Nov 7, 1997
• Grant date: Feb 16, 1999
• Expiry date: Nov 7, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61L2/0011
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.